New pill targets blood cancers in early human trial

NCT ID NCT07064122

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called AZD2962, which blocks a protein called IRAK4 involved in cancer growth. The study includes about 72 people with certain blood cancers (myelodysplastic syndromes or chronic myelomonocytic leukemia) that have not responded to prior treatments. Researchers are giving the drug as a daily pill, either alone or with other medicines, to check its safety, find the right dose, and see if it helps shrink the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD2962 (an IRAK4 inhibitor taken as a pill)
What this could lead to: If successful, this could point toward a new treatment option for certain blood cancers that have stopped responding to standard therapies.
What could go wrong: This is a very early (Phase 1/2) and small trial (72 people). The drug may not work or may cause side effects. It is too soon to know if it will be safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSPLASTIC CHRONIC MYELOMONOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelomonocytic leukemia hematopoietic and lymphoid cell neoplasm hereditary sensory and autonomic neuropathy myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAEMATOLOGIC NEOPLASMS

Contacts and locations

Locations

Research Site
NOT_YET_RECRUITING

Miami, Florida, 33136, United States
Research Site
RECRUITING

Tampa, Florida, 33612, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
RECRUITING

Heidelberg, 3084, Australia
Research Site
RECRUITING

Melbourne, 3000, Australia
Research Site
RECRUITING

Shinagawa-ku, 141-0022, Japan
Research Site
RECRUITING

Yoshida-gun, 910-1193, Japan
Research Site
WITHDRAWN

Seoul, 05505, South Korea
Research Site
WITHDRAWN

Seoul, 3722, South Korea
Research Site
RECRUITING

Barcelona, 08035, Spain
Research Site
RECRUITING

Madrid, 28027, Spain
Research Site
RECRUITING

Madrid, 28033, Spain
Research Site
RECRUITING

Pamplona, 31008, Spain
Research Site
RECRUITING

Salamanca, 37007, Spain
Research Site
WITHDRAWN

Valencia, 46026, Spain
Research Site
NOT_YET_RECRUITING

Kaohsiung City, 83301, Taiwan
Research Site
NOT_YET_RECRUITING

Tainan, 70403, Taiwan
Research Site
RECRUITING

Taipei, 100, Taiwan
Research Site
RECRUITING

London, SE5 9RS, United Kingdom
Research Site
RECRUITING

London, W1T 7HA, United Kingdom
Research Site
RECRUITING

Manchester, M20 4BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.